Inventor · disambiguated record
David Charles Blakey
Also filed as: BLAKEY DAVID · BLAKEY DAVID CHARLES
13 granted patents·13 pending applications·195 citations·filing 1994–2025
92Inventor score
Top patents by PatentIndex Score
26 records- 0195US7973140B2Antibodies directed to angiopoietin-2 and uses thereofMEDIMMUNE LTD·Filed 2005·Granted Jul 5, 2011·36 cites·11 claims
- 0284US8834880B2Antibodies directed to angiopoietin-2 and uses thereofMEDIMMUNE LTD·Filed 2012·Granted Sep 16, 2014·5 cites·4 claims
- 0383US7754859B2Targeted binding agents directed to PDGFR-alpha and uses thereofASTRAZENECA AB·Filed 2007·Granted Jul 13, 2010·7 cites·18 claims
- 0481US5665357AAntibodies recognizing tumor associated antigen CA 55.1ZENECA LTD·Filed 1994·Granted Sep 9, 1997·68 cites·15 claims
- 0578US10066011B2Antibodies directed to angiopoietin-2 and uses thereofMEDIMMUNE LTD·Filed 2014·Granted Sep 4, 2018·2 cites·15 claims
- 0676US7030123B2Indole derivatives with vascular damaging activityASTRAZENECA AB·Filed 2001·Granted Apr 18, 2006·10 cites·10 claims
- 0775US11965163B2HNF4a saRNA compositions and methods of useMINA THERAPEUTICS LTD·Filed 2021·Granted Apr 23, 2024·0 cites·12 claims
- 0872US2023031703A1Stabilized hnf4a sarna compositions and methods of useMINA THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 0970US6339070B1Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moietyZENECA LTD·Filed 1998·Granted Jan 15, 2002·37 cites·34 claims
- 1067US11162099B2HNF4A saRNA compositions and methods of useMINA THERAPEUTICS LTD·Filed 2018·Granted Nov 2, 2021·0 cites·4 claims
- 1167US2024018519A1Stabilized saRNA Compositions and Methods of UseMINA THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1264US11447773B2Stabilized HNF4A saRNA compositions and methods of useMINA THERAPEUTICS LTD·Filed 2018·Granted Sep 20, 2022·0 cites·9 claims
- 1364US5985281AChemical compoundsZENECA LTD·Filed 1995·Granted Nov 16, 1999·26 cites·39 claims
- 1460US8697664B2Targeted binding agents directed to PDGRF-alpha and uses thereofLAING NAOMI·Filed 2010·Granted Apr 15, 2014·1 cites·23 claims
- 1558US2009123474A1Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancerASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 1657US2009324601A1Targeted binding agents directed to pdgfr-alpha and uses thereofASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 1755US2012288497A1Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancerBLAKEY DAVID CHARLES·Filed 2012·Application pending·0 cites
- 1854US2012052073A1Antibodies Directed to Angiopoietin-2 And Uses ThereofGREEN LARRY L·Filed 2011·Application pending·0 cites
- 1954US2016251421A1Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancerMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 2052US2011097321A1Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancerASTRAZENECA AB·Filed 2010·Application pending·0 cites
- 2152US2014023654A1Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancerMEDLMMUNE LTD·Filed 2013·Application pending·0 cites
- 2250US2020208152A1Stabilized sarna compositions and methods of useMINA THERAPEUTICS LTD·Filed 2018·Application pending·0 cites
- 2346US2025263702A1Rnai agents targeting cideb and related methodsFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2025·Application pending·0 cites
- 2445US2021254069A1Combination therapies comprising c/ebp alpha sarnaMINA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2544US2021024928A1C/ebp alpha sarna compositions and methods of useMINA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 2634US6436691B1Chemical compoundsZENECA LTD·Filed 1996·Granted Aug 20, 2002·3 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when David Charles Blakey files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →